checkAd
    Startseite > Aktien > Amylyx Pharmaceuticals > Nachrichten
    Amylyx Pharmaceuticals Aktie
    1,7700
     
    USD
    +0,57 %
    +0,0100 USD
    Letzter Kurs 02:00:00 Nasdaq
    1,7600
     
    USD
    7.900 STK
    Geldkurs 07.06.24
    1,7700
     
    USD
    15.500 STK
    Briefkurs 07.06.24
    ISIN: US03237H1014 · WKN: A3DCEY · SYM: AMLX · USA

    Neueste Nachrichten

    Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    04.06.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
    09.05.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference
    08.05.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
    02.05.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
    10.04.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)
    08.04.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
    08.04.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    AMYLYX PHARMACEUTICALS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX
    06.04.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO/ALBRIOZA from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
    04.04.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
    14.03.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations
    09.03.24 · Business Wire (engl.) · Amylyx Pharmaceuticals
    Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
    08.03.24 · Business Wire (engl.) · Amylyx Pharmaceuticals